FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 342:1622-1626 June 1, 2000 Number 22 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The cardiovascular effects of sildenafil are important because of the frequent presence of underlying cardiac disease in men with erectile dysfunction and reports indicating serious cardiac events temporally associated with the use of this drug.

Methods We assessed the systemic, pulmonary, and coronary hemodynamic effects of oral sildenafil (100 mg) in 14 men (mean [±SD] age, 61±11 years) with severe stenosis of at least one coronary artery (stenosis of >70 percent of the vessel diameter) who were scheduled to undergo percutaneous coronary revascularization. Blood-flow velocity and flow reserve were assessed with a Doppler guidewire in 25 coronary arteries, including 13 severely diseased arteries (mean degree of stenosis, 78±7 percent) and 12 arteries without stenosis, used as a reference; maximal hyperemia was induced (to assess flow reserve) with the intracoronary administration of adenosine both before and after sildenafil.

Results Oral sildenafil produced only small decreases (<10 percent) in systemic arterial and pulmonary arterial pressures, and it had no effect on pulmonary-capillary wedge pressure, right atrial pressure, heart rate, or cardiac output. There were no significant changes in average peak coronary flow velocity, coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. Coronary flow reserve at base line was lower in the stenosed arteries (1.26±0.26) than in the reference arteries (2.19± 0.44) and increased about 13 percent in both groups of arteries combined after the administration of sildenafil (from 1.70±0.59 to 1.92±0.72, P=0.003). The ratio of coronary flow reserve in coronary arteries with stenosis to that in the reference arteries (0.57±0.14) was not affected by sildenafil.

Conclusions No adverse cardiovascular effects of oral sildenafil were detected in men with severe coronary artery disease.

Source Information

From the Cardiovascular Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia. Presented in preliminary form at the 72nd Scientific Sessions of the American Heart Association, Atlanta, November 7–10, 1999.

Address reprint requests to Dr. Herrmann at the Hospital of the University of Pennsylvania, 9 Founder's Pavilion, 3400 Spruce St., Philadelphia, PA 19104, or at herrmann{at}mail.med.upenn.edu.

Full Text of this Article

Related Letters:

Hemodynamic Effects of Sildenafil
Malozowski S., Sahlroot J. T., Herrmann H. C.
Extract | Full Text  
N Engl J Med 2000; 343:967-968, Sep 28, 2000. Correspondence

This article has been cited by other articles:

• Rietema, H., Holverda, S., Bogaard, H. J., Marcus, J. T., Smit, H. J., Westerhof, N., Postmus, P. E., Boonstra, A., Vonk-Noordegraaf, A. (2008). Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31: 759-764 [Abstract] [Full Text]  
• Guazzi, M., Samaja, M., Arena, R., Vicenzi, M., Guazzi, M. D. (2007). Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure. J Am Coll Cardiol 50: 2136-2144 [Abstract] [Full Text]  
• Goldsmith, S. R. (2007). Type 5 Phosphodiesterase Inhibition in Heart Failure: The Next Step. J Am Coll Cardiol 50: 2145-2147 [Full Text]  
• Lewis, G. D., Shah, R., Shahzad, K., Camuso, J. M., Pappagianopoulos, P. P., Hung, J., Tawakol, A., Gerszten, R. E., Systrom, D. M., Bloch, K. D., Semigran, M. J. (2007). Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension. Circulation 116: 1555-1562 [Abstract] [Full Text]  
• Nagendran, J., Archer, S. L., Soliman, D., Gurtu, V., Moudgil, R., Haromy, A., St. Aubin, C., Webster, L., Rebeyka, I. M., Ross, D. B., Light, P. E., Dyck, J. R.B., Michelakis, E. D. (2007). Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility. Circulation 116: 238-248 [Abstract] [Full Text]  
• Oliver, J. J., Melville, V. P., Webb, D. J. (2006). Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension. Hypertension 48: 622-627 [Abstract] [Full Text]  
• Kiowski, W., Brunner, H., Schalcher, C. (2006). Sex, the heart, and heart failure.. SEMIN CARDIOTHORAC VASC ANESTH 10: 256-258 [Abstract]  
• Lewis, G. D., Witzke, C., Colon-Hernandez, P., Guerrero, J. L., Bloch, K. D., Semigran, M. J. (2006). Sildenafil Improves Coronary Artery Patency in a Canine Model of Platelet-Mediated Cyclic Coronary Occlusion After Thrombolysis. J Am Coll Cardiol 47: 1471-1477 [Abstract] [Full Text]  
• Robinson, S D, Ludlam, C A, Boon, N A, Newby, D E (2006). Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 92: 170-176 [Abstract] [Full Text]  
• Fries, R., Shariat, K., von Wilmowsky, H., Bohm, M. (2005). Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy. Circulation 112: 2980-2985 [Abstract] [Full Text]  
• Semigran, M. J. (2005). Type 5 Phosphodiesterase Inhibition: The Focus Shifts to the Heart. Circulation 112: 2589-2591 [Full Text]  
• Borlaug, B. A., Melenovsky, V., Marhin, T., Fitzgerald, P., Kass, D. A. (2005). Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans. Circulation 112: 2642-2649 [Abstract] [Full Text]  
• Fung, E., Fiscus, R. R., Yim, A. P. C., Angelini, G. D., Arifi, A. A. (2005). The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery. Chest 128: 3065-3073 [Abstract] [Full Text]  
• Thethi, T. K., Asafu-Adjaye, N. O., Fonseca, V. A. (2005). Erectile Dysfunction. Clin. Diabetes 23: 105-113 [Abstract] [Full Text]  
• Takimoto, E., Champion, H. C., Belardi, D., Moslehi, J., Mongillo, M., Mergia, E., Montrose, D. C., Isoda, T., Aufiero, K., Zaccolo, M., Dostmann, W. R., Smith, C. J., Kass, D. A. (2005). cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism. Circ. Res. 96: 100-109 [Abstract] [Full Text]  
• Guazzi, M., Tumminello, G., Di Marco, F., Fiorentini, C., Guazzi, M. D. (2004). The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44: 2339-2348 [Abstract] [Full Text]  
• Kloner, R. A. (2004). Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction. Circulation 110: 3149-3155 [Full Text]  
• Raja, S. G., Nayak, S. H. (2004). Sildenafil: Emerging Cardiovascular Indications. Ann. Thorac. Surg. 78: 1496-1506 [Abstract] [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Webster, L. J., Michelakis, E. D., Davis, T., Archer, S. L. (2004). Use of Sildenafil for Safe Improvement of Erectile Function and Quality of Life in Men With New York Heart Association Classes II and III Congestive Heart Failure: A Prospective, Placebo-Controlled, Double-blind Crossover Trial. Arch Intern Med 164: 514-520 [Abstract] [Full Text]  
• Fox, K. M., Thadani, U., Ma, P. T.S., Nash, S. D., Keating, Z., Czorniak, M. A., Gillies, H., Keltai, M., on behalf of the CAESAR I investigators, (2003). Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 24: 2206-2212 [Abstract] [Full Text]  
• Vlachopoulos, C., Hirata, K., O'Rourke, M. F (2003). Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 8: 243-248 [Abstract]  
• Reffelmann, T., Kloner, R. A. (2003). Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 59: 441-449 [Abstract] [Full Text]  
• Reffelmann, T., Kloner, R. A. (2003). Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease. Circulation 108: 239-244 [Full Text]  
• Sarfati, M., Mateo, V., Baudet, S., Rubio, M., Fernandez, C., Davi, F., Binet, J.-L., Delic, J., Merle-Beral, H. (2003). Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101: 265-269 [Abstract] [Full Text]  
• Jackson, G. (2002). Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. Eur Heart J Suppl 4: H19-H23 [Abstract]  
• Emmick, J.T., Stuewe, S.R., Mitchell, M. (2002). Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 4: H32-H47 [Abstract]  
• Tracqui, A, Miras, A, Tabib, A, Raul, J S, Ludes, B, Malicier, D (2002). Fatal overdosage with sildenafil citrate (Viagra1): first report and review of the literature. Hum Exp Toxicol 21: 623-629 [Abstract]  
• Schalcher, C., Schad, K., Brunner-La Rocca, H. P., Schindler, R., Oechslin, E., Scharf, C., Suetsch, G., Bertel, O., Kiowski, W. (2002). Interaction of Sildenafil With cAMP-Mediated Vasodilation In Vivo. Hypertension 40: 763-767 [Abstract] [Full Text]  
• Halcox, J. P. J., Nour, K. R. A., Zalos, G., Mincemoyer, R., Waclawiw, M. A., Rivera, C. E., Willie, G., Ellahham, S., Quyyumi, A. A. (2002). The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40: 1232-1240 [Abstract] [Full Text]  
• Desouza, C., Parulkar, A., Lumpkin, D., Akers, D., Fonseca, V. A. (2002). Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes. Diabetes Care 25: 1336-1339 [Abstract] [Full Text]  
• Gewaltig, M. T, Kojda, G. (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55: 250-260 [Abstract] [Full Text]  
• Jackson, G. (2002). Cardiovascular safety in erectile dysfunction treatment. British Journal of Diabetes & Vascular Disease 2: 301-304 [Abstract]  
• Rochira, V., Granata, A. R. M., Balestrieri, A., Madeo, B., Carani, C. (2002). Effects of Sildenafil on Nocturnal Penile Tumescence and Rigidity in Normal Men: Randomized, Placebo-Controlled, Crossover Study. J Androl 23: 566-571 [Abstract] [Full Text]  
• Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., Archer, S. (2002). Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide. Circulation 105: 2398-2403 [Abstract] [Full Text]  
• Arruda-Olson, A. M., Mahoney, D. W., Nehra, A., Leckel, M., Pellikka, P. A. (2002). Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease: A Randomized Crossover Trial. JAMA 287: 719-725 [Abstract] [Full Text]  
• Marwick, T. H. (2002). Safe Sex for Men With Coronary Artery Disease: Exercise, Sildenafil, and Risk of Cardiac Events. JAMA 287: 766-767 [Full Text]  
• Cohan, P., Korenman, S. G. (2001). Erectile Dysfunction. J. Clin. Endocrinol. Metab. 86: 2391-2394 [Full Text]  
• Kirby, M. G (2001). Updating erectile dysfunction. British Journal of Diabetes & Vascular Disease 1: 143-145  
• Siegel, R. L., Glasser, D. B. (2001). Cost-Effectiveness of Sildenafil. ANN INTERN MED 134: 250-250 [Full Text]  
• Przyklenk, K., Kloner, R. A. (2001). Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 37: 286-292 [Abstract] [Full Text]  
• Phillips, B. G., Kato, M., Pesek, C. A., Winnicki, M., Narkiewicz, K., Davison, D., Somers, V. K. (2000). Sympathetic Activation by Sildenafil. Circulation 102: 3068-3073 [Abstract] [Full Text]  
• Michelakis, E., Tymchak, W., Archer, S. (2000). Sildenafil: from the bench to the bedside. CMAJ 163: 1171-1175 [Abstract] [Full Text]  
• Malozowski, S., Sahlroot, J. T., Herrmann, H. C. (2000). Hemodynamic Effects of Sildenafil. NEJM 343: 967-968 [Full Text]  
• (2000). Viagra Does Not Affect Coronary Hemodynamics. Journal Watch Cardiology 2000: 2-2 [Full Text]  
• (2000). General Medicine: Hemodynamic Effects of Sildenafil in Patients with Coronary Disease. JWatch Psychiatry 2000: 9-9 [Full Text]  
• (2000). Hemodynamic Effects of Sildenafil in Patients with Coronary Disease. JWatch General 2000: 1-1 [Full Text]